Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma

Roche

Status: Completed

Conditions: Metastatic Cancers

Study type: Observational

Funder types: Industry

Identifiers

NCT02663232

ML30089

Details and patient eligibility

About

This is a national, multicenter, cross-sectional epidemiological study in adult Spanish participants diagnosed with advanced or metastatic melanoma.

Enrollment: 264 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Valid tumor samples from participants diagnosed with Stage IIIc or IV melanoma
• Written informed consent granted

Exclusion criteria

• Do not fulfill one or more inclusion criteria

Trial design

264 participants in 1 patient group

Metastatic melanoma

Description:

Participants with metastatic melanoma who attend their physicians during the 18-month recruitment period and have valid biological samples available for BRAF mutation testing will be included in the study. There will be no intervention in this study.